Skip to main content

Advertisement

SpringerLink
Log in

Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Docetaxel is one of the most active drugs in second-line therapy for non-small-cell-lung-carcinoma (NSCLC). The aim of this multicenter study was to evaluate the safety and efficacy of weekly low-dose docetaxel. Forty-two patients with advanced NSCLC pretreated with cisplatinum-based chemotherapy were enrolled. Docetaxel was administered at a dose of 25 mg/m2 weekly for 12 consecutive weeks. A total of 386 doses were given with a median number of 10 doses per patient (range: 3–12). Treatment showed low incidence of hematologic toxicity and modest non-hematologic toxicity. An episode of grade 4 thrombocytopenia was reported but no episodes of grade 3 or 4 neutropenia. Most frequent non-hematologic toxicities were asthenia and alopecia. Response rate was 10.5% and median survival time (MST) was 12.8 weeks. Weekly treatment with 25 mg/m2 docetaxel for 12 consecutive weeks appears to be a feasible and active regimen with mild toxicity in heavily pretreated NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. A Ardizzoia P Tagliabue M Giordano et al. (2002) ArticleTitleWeekly docetaxel: a multicenter phase II trial in elderly pre-treated advanced NSCLC patients. Ann Oncol 13 E17

    Google Scholar 

  2. D Belotti V Vergani T Drudis et al. (1996) ArticleTitleThe microtubule-affecting drug paclitaxel has antiangiogenetic activity. Clin Cancer Res 2 1843–1849 Occurrence Handle1:CAS:528:DyaK28Xnt1SitLo%3D Occurrence Handle9816139

    CAS  PubMed  Google Scholar 

  3. FV Fossella R DeVore RN Kerr et al. (2000) ArticleTitleRandomised phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 2354–2362 Occurrence Handle1:CAS:528:DC%2BD3cXkvFWrsLg%3D Occurrence Handle10856094

    CAS  PubMed  Google Scholar 

  4. J Hainsworth HA Burris III JB Erland M Thomas A Greco (1998) ArticleTitlePhase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16 2164–2168 Occurrence Handle1:STN:280:DyaK1c3ovFCmtQ%3D%3D Occurrence Handle9626217

    CAS  PubMed  Google Scholar 

  5. N Klauber S Parangi E Hamel E Flynn RJ D’Amato (1997) ArticleTitleInhibition of angiogenesis in vivo by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57 81–86 Occurrence Handle1:CAS:528:DyaK2sXjvFOmtw%3D%3D

    CAS  Google Scholar 

  6. LM Levasseur HK Slocum YM Rustum WR Greco (1998) ArticleTitleModeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58 5749–5761 Occurrence Handle1:CAS:528:DyaK1MXivFWj Occurrence Handle9865733

    CAS  PubMed  Google Scholar 

  7. RC Lilenbaum MA Schwartz L Seigel et al. (2001) ArticleTitlePhase II trial of weekly docetaxel in second-line therapy for non small cell lung carcinoma. Cancer 15 2158–2163 Occurrence Handle10.1002/1097-0142(20011015)92:8<2158::AID-CNCR1558>3.0.CO;2-2

    Article  Google Scholar 

  8. VA Miller FV Fossella R DeVore R Kerr J Crawford D Karp et al. (1999) ArticleTitleDocetaxel benefits lung cancer symptoms and quality of life in a randomised phase III study of non small cell lung cancer patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 18 491a

    Google Scholar 

  9. CJL Murray AD Lopez (Eds) (1996) The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press Cambridge

    Google Scholar 

  10. InstitutionalAuthorNameNon Small Cell Lung Cancer Collaborative Group (1995) ArticleTitleChemotherapy in non small cell lung cancer: a metanalysis using updated data on individual patients from 52 randomised clinical trial. Br Med J 311 899–909 Occurrence Handle1:STN:280:BymC1MjhsVQ%3D

    CAS  Google Scholar 

  11. DM Parkin P Pisan J Ferlay (1999) ArticleTitleGlobal cancer statistics. CA cancer J Clin 49 33–64 Occurrence Handle10200776

    PubMed  Google Scholar 

  12. FA Shepherd J Dancey R Ramlau et al. (2000) ArticleTitleProspective randomised trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 2095–2103 Occurrence Handle1:CAS:528:DC%2BD3cXktVyjsLc%3D Occurrence Handle10811675

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S. Gerardo Hospital, Monza-Milan, Italy

    A. Ardizzoia, M. Acquati & F. Malugani on behalf of POLONORD Group

  2. Vimercate Hospital, Vimercatey

    D. Fagnani & P. Tagliabue

  3. S. Anna Hospital, Como, Italy

    M. Giordano

  4. A. Manzoni Hospital, Lecco

    M. Visini

  5. Fatebenefratelli Hospital, Milan, Italy

    A. Scanni

  6. Serbelloni Hospital, Gorgonzola, Italy

    A. Quattrone

  7. Sondrio Hospital, Sondrio, Italy, Italy

    O. Fusco

  8. Sacra Famiglia Hospital, Erba-Como, Italy

    C. Vergani

  9. Valduce Hospital, Como, Italy

    C. Casartelli

Authors
  1. A. Ardizzoia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Acquati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Fagnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Visini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Scanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Quattrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. O. Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Vergani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Casartelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P. Tagliabue
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. Malugani on behalf of POLONORD Group
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Ardizzoia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ardizzoia, A., Acquati, M., Fagnani, D. et al. Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study . Lung 182, 1–8 (2004). https://doi.org/10.1007/s00408-003-1039-5

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-003-1039-5

Keywords

Search

Navigation